Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience

Frallonardo, Luisa; Vimercati, Antonella; Novara, Roberta; Cherola, Lepera; Ilaria, Ferrante; Chiarello, Giulia; Cicinelli, Rossana; Mongelli, Michele; Gaetano, Brindicci; Vladimiro, Segala Francesco; Rita, Santoro Carmen; Fiore, Bavaro Davide; Laforgia, Nicola; Cicinelli, Ettore; Annalisa, Saracino; Gennaro, Francesco Di

doi:10.1080/20477724.2023.2188839

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Frallonardo et al report a series of 13 pregnant women with SARS-CoV-2 infection that were treated with neutralizing monoclonal antibody (Sotrovimab). The results revealed no adverse reactions and good clinical outcomes in all patients [ 62 ].…”

Section: Pregnancy and Covid-19 Outcomes Associated With Endothelial ...mentioning

confidence: 99%

Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review

Sekulovski,

Mileva,

Chervenkov

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Pregnancy with SARS-CoV-2 infection can raise the risk of many complications, including severe COVID-19 and maternal–fetal adverse outcomes. Additionally, endothelial damage occurs as a result of direct SARS-CoV-2 infection, as well as immune system, cardiovascular, and thrombo-inflammatory reactions. In this narrative review, we focus on endothelial dysfunction (ED) in pregnancy, associated with obstetric complications, such as preeclampsia, fetal growth retardation, gestational diabetes, etc., and SARS-CoV-2 infection in pregnant women that can cause ED itself and overlap with other pregnancy complications. We also discuss some shared mechanisms of SARS-CoV-2 pathophysiology and ED.

show abstract

Section: Pregnancy and Covid-19 Outcomes Associated With Endothelial ...mentioning

confidence: 99%

Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review

Sekulovski,

Mileva,

Chervenkov

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

COVID-19 therapeutics for the pregnant patient

Triebwasser,

Davies,

Nestani

2024

Seminars in Perinatology

View full text Add to dashboard Cite

Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis

Di Gennaro,

Guido,

Frallonardo

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background Clinical evidence suggests that pregnant women are more vulnerable to COVID-19, since they are at increased risk for disease progression and for obstetric complications, such as premature labor, miscarriage, preeclampsia, cesarean delivery, fetal growth restriction and perinatal death. Despite this evidence, pregnant women are often excluded from clinical trials, resulting in limited knowledge on COVID-19 management. The aim of this systematic review and meta-analysis is to provide better evidence on the efficacy and safety of available COVID-19 treatment in pregnant women. Methods Four authors searched major electronic databases from inception until 1 st November-2022 for controlled trials/observational studies, investigating outcomes after the administration of anti-SARS-CoV-2 treatments in pregnant women affected by COVID-19. The analyses investigated the cumulative incidence of delivery and maternal outcomes in pregnant women, comparing those taking active medication vs standard care. Risk ratios (RRs) with 95% confidence intervals were calculated. Statistical significance was assessed using the random effects model and inverse-variance method. This systematic review and meta-analysis was conducted in accordance with the updated 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol has been registered in Prospero (number registration: CRD42023397445). Results From initially 937 non duplicate records, we assessed the full texts of 40 articles, finally including ten studies. In six studies, including 1627 patients, the use of casirivimab/imdevimab (CAS/IMD), remdesivir, and IFN-alpha 2b significantly decreased the need of cesarean section ((RR = 0.665; 95%CI: 0.491–0.899; p = 0.008; I 2 = 19.5%;) (Table 1, (Fig. 1). Treatments did not decrease the risk of preterm delivery, admission to neonatal ICU, or stillbirth/perinatal loss (p-values > 0.50 for all these outcomes) and did not prevent the progression of disease towards severe degrees (k = 8; 2,374 pregnant women; RR = 0.778; 95%CI: 0.550–1.099; p = 0.15; I 2 = 0%). Moreover, the use of medications during pregnancy did not modify the incidence of maternal death in two studies (Table 2). Conclusions To our analysis, CAS/IMD, remdesivir, and IFN alpha 2b reduced the number of cesarean sections but demonstrated no effect on disease progression and other obstetric and COVID-19 related outcomes. The inability to evaluate the influence of viral load on illness development in pregnant women was attributed to lack of data. In our systematic review, no major side effects were reported. Though, it is essential for the medical community to focus more on clinical trials and less on episodic case reports and case series, with standardization of fetal and maternal outcomes.

show abstract

Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience

Cited by 3 publications

References 23 publications

Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review

Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review

COVID-19 therapeutics for the pregnant patient

Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis

Contact Info

Product

Resources

About